Late Breaking Abstract Parallel Session 3
Nov
11
2025
Convention Center: Hall A (General Session), Concourse Level
10:30 AM
- 12:00 PM
Live Streamed
Captured
World Class Speakers
Description
Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.Presentations
10:30 AM
- 10:45 AM
May
18
2026
Washington, D.C.
Lactulose and Tai-Chi Prevent Falls in Patients with Cirrhosis: The LiveSMART Randomized Controlled Trial
Elliot B. Tapper, MD, FAASLD
, Abstract Presenter
11:30 AM
- 11:45 AM
May
18
2026
Washington, D.C.
Dual GLP-1 and Glucagon Receptor Agonist, Mazdutide, Resolved Steatosis in >60% of Participants with MASLD and Obesity in a Multicenter, Randomized Phase 2 Trial
Rohit Loomba, MD, MHSc, FAASLD
, Abstract Presenter
11:45 AM
- 12:00 PM
May
18
2026
Washington, D.C.
A Phase 2, Multicenter, Randomized, Placebo-Controlled Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis
Mazen Noureddin
, Abstract Presenter
11:15 AM
- 11:30 AM
May
18
2026
Washington, D.C.
Combination therapy with HT-101 and HT-102 achieves rapid and progressive HBsAg loss in HBeAg-negative, nucleos(t)ide analogues-suppressed patients: 12-week interim results from an ongoing multicentre, open-label phase Ib/IIa study
Andrew Keaveny, MD, FRCPI, FAASLD
, Abstract Presenter
Objectives
- Review findings from recent clinical trials related to treatments for cirrhosis, MASLD, and HCC.